

List of Figures

Figures	Title	Page No.
Chapter 1		
1.1	Distribution of bacterial communities in different parts of human gastrointestinal tract with varying pH.	3
1.2	Development of the intestinal microbiota	4
1.3	Localization of dominant bacterial groups in the intestine	5
1.4	Mutualistic commensal microbiome possessing immunomodulatory effect sustains healthy immune homeostasis	7
1.5	Metabolic conversion of luminal substance by gut microbiota	9
1.6	Potential targets of FXR and TGR5 agonists in Non-alcoholic steatohepatitis	11
1.7	A schematic representation of major functions of probiotics in humans.	13
1.8	Commercially available probiotic <i>E. coli</i> Nissle 1917 products	18
1.9	Pathways of ROS formation	24
1.10	Targets of free radicals	29
1.11	Natural antioxidants and their classification	31
1.12	Sources and cellular response of ROS	33
1.13	Absorption and distribution of ethanol in humans.	34
1.14	Metabolism of ethanol in mammals	35
1.15	Reactions involved in ethanol oxidation	36
1.16	Hepatic ethanol metabolism	38
1.17	Interaction of ethanol with malnutrition	39
1.18	Schematic representation of various deleterious effects of ethanol and acetaldehyde.	40
1.19	Diagrammatic representation of the metabolism and biological activities of NAD ⁺	44
1.20	Diagrammatic representation of the metabolism and biological activities of NADH	45

1.21	Schematic diagram showing association between oxidative stress, PARP mediated and decline in NAD ⁺ /NADH ratio and NAD ⁺ dependent functions with aging.	46
1.22	A schematic representation of mechanisms governing aging in colon	51
1.23	Implications of Mitochondrial ROS in ageing	52
1.24	The Harmonis hypothesis of Calorie Restriction	53
1.25	Reactions depicting reduced and oxidized states of Pyrroloquinoline Quinone	54
1.26	<i>pqq</i> gene clusters in different bacterial species	55
1.27	A representation of summarized functions of PQQ in bacteria, plants and animals	59
1.28	Schematic illustration showing (A) the involvement of NO-sensitive Ras-mediated signaling pathways in the proliferation of Ras-NIH3T3 cells induced by PQQ.	60
1.29	Histological hallmarks of Crohn's disease and Ulcerative colitis.	62
1.30	Inflammatory Bowel Disease etiopathogenesis patterns	63
1.31	Mucosal immune response in IBD	64
1.32	Schematic representation of various factors that can influence the susceptibility, onset, severity, and responsiveness to DSS-induced colitis.	68
1.33	Redox responses in GIT.	70

Chapter 2

2.1	A schematic representation of protocol followed for chronic ethanol administration in rats	77
2.2	Experimental groups and treatments for evaluating their effect against chronic ethanol ingestion	78
2.3	Standardization of optimal ethanol dose and duration	84
2.4	Confirmation of pBBR1 MCS2-pqq plasmid by Restriction Enzyme digestion	85
2.5	<i>E. coli</i> strains grown on Luria broth with and without kanamycin	86

2.6	Effect of PQQ, EcN-4 and Vitamin C pre-treatments on oxidative damage and antioxidant status measured as MDA levels in Plasma (A) and Liver (B), and reduced hepatic glutathione levels (C) in acute ethanol fed rats.	87
2.7	Effect of EcN-4 on hepatic oxidative damage, antioxidant status and liver function parameters in chronic ethanol fed rats.	88
2.8	Histological sections of liver tissue of the rats treated with chronic ethanol with or without probiotic co-treatments	89
2.9	Effect of EcN-4 on oxidative damage and antioxidant status in extra hepatic tissues (blood, colonic and kidney) of chronic ethanol fed rats	90
2.10	mRNA expression levels of Fatty acid synthase (A) and Acyl Coenzyme A oxidase (B) in hepatic tissue of rats co-treated with EcN-4 and chronic ethanol	92

Chapter 3

3.1	Chemical structure of Rotenone	103
3.2	<i>pqqABCDE</i> gene clusters from <i>G. suboxydans</i>	105
3.3	Schematic representation of strategy. Rats were randomly divided between different groups.	108
3.4	Gradient PCR and agarose gel electrophoresis of amplicons	110
3.5	RE digestion pattern of pTPQQ-1 plasmid generated as result of ligation of pqqABCDE genes in pTZ57R/T vector	111
3.6	Body weight gain and antioxidant profile of rats treated with rotenone. Body weight gain (A), Hepatic lipid peroxidation (B), Hepatic GSH (C), Hepatic CAT activity (D), Hepatic SOD activity (E) and Hepatic Mit-SOD activity	112
3.7	Body weight profile in rotenone induced accelerated aging model	113
3.8	Hepatic antioxidant status of animals treated with PQQ producing EcN-5 in rotenone induced accelerated aging model	114
3.9	Hepatic Mitochondrial SOD activity (A), mitochondrial content (B) and PGC-1 α mRNA expression of animals treated with PQQ producing EcN-5 in rotenone induced accelerated aging model.	115

Chapter 4

4.1	Schematic representation of strategy for different animal groups receiving respective treatments in naturally aging rat model.	123
4.2	Antioxidant status in blood, liver and colon of young and aged Charles Foster rats	126
4.3	Blood lipid profile of young and aged Charles Foster rats	127
4.4	Antioxidant status in hepatic and colonic tissues of aging rats treated with PQQ producing EcN-5	129
4.5	Mitochondrial metabolism, biogenesis and content in aging rats treated with PQQ producing EcN-5	130
4.6	mRNA expression of lipid metabolizing genes.	132
4.7	Effect of PQQ on <i>C. elegans</i> survival after H ₂ O ₂ exposure (A) and heat (B).	134

Chapter 5

5.1	Strategy for animal experimentation.	143
5.2	Cloning and confirmation of 6a-pqq-1 plasmid.	146
5.3	Cloning and confirmation of 6a-pqq-2 plasmid	147
5.4	Cloning and confirmation of pGRG-36- <i>vgb-gfp</i> -cTacpqq plasmid	147
5.5	Confirmation of integration <i>vgb</i> , <i>gfp</i> and <i>pqqABCDE</i> genes in EcN genome.	148
5.6	PQQ producing EcN strains secreting gluconic acid in vitro (A), in vivo (B) and PQQ in vivo (C).	150
5.7	Colonic SCFAs profile in starch fed rats co-treated with recombinant EcN strains producing PQQ	151

Chapter 6

6.1	Schematic diagram representing DSS and EcN strains treatment.	160
6.2	A schematic diagram of procedures operated during <i>C. rodentium</i> infection experiment on mice.	161
6.3	Colonization of probiotic EcN in mouse intestine.	164
6.4	Body weight and disease score of mice treated with EcN strains in DSS-induced colitis.	165

6.5	Colon length (A), spleen weight (B) and colonic histology scores (C) of mice treated with EcN strains in DSS-induced colitis.	166
6.6	Effect of post-treatment of EcN-wt and EcN-1 in DSS induced murine colitis.	166
6.7	mRNA expression of cytokines from colon of mice treated with EcN strains in DS-induced colitis.	167
6.8	DUOX 1&2 protein expression in whole colon of mice treated with EcN strains in DSS-induced colitis.	168
6.9	<i>C. rodentium</i> shedding in feces (A & B) and colonization in colon (C) & Caecum (D) after infection in mice treated with EcN strains.	169
6.10	Colon length (A) and spleen weight (B) of mice infected with <i>C. rodentium</i> and treated with EcN strains.	170
6.11	mRNA expression of colonic cytokines in mice infected with <i>C. rodentium</i> and treated with EcN strains.	171
6.12	<i>In Vitro C. rodentium</i> growth inhibition by EcN-wt and EcN- <i>pqq</i> .	172

List of Tables

Table No.	Title	Page No.
Chapter 1		
1.1	Nonpathogenic bacterial members of the intestinal microbiota with immune effects	6
1.2	Commonly used probiotic strains and their beneficial characteristics	15,16
1.3	Genetically modified probiotics in health and disease	20,21
1.4	ROS mediated production of Oxidized products of Amino acids	28
1.5	Chemical structure and application of common synthetic antioxidants	32
1.6	Representation of different genes involved in PQQ biosynthesis	56
1.7	Mouse models of colitis with altered barrier, innate or adaptive immune responses	65,66
Chapter 2		
2.1	Plasmids and Bacterial strains	75,76
2.2	PQQ secreting in supernatant by probiotic <i>E. coli</i> strains	86
2.3	Body weight gain and lipid profile of chronic ethanol fed rats treated along with Vitamin C, PQQ and PQQ secreting EcN	93
2.4	PQQ concentration in fecal matter and liver homogenate of chronic ethanol fed rats treated along with Vitamin C, PQQ and PQQ secreting EcN	95
2.5	Short chain fatty acids (SCFAs) concentration in colonic matter of experimental rats	95
2.6	Effect of EcCFR16:: vgb-gfp (pqq) secreting PQQ on antioxidant status and lipid profile in chronic ethanol treated rats	96,97
Chapter 3		
3.1	Plasmids and bacterial strains	106,107
3.2	Primer sequences used for qRT-PCR	109

Chapter 4

4.1	Plasmids and bacterial strains	122
4.2	Primer sequences used for qRT-PCR	124
4.3	Plasma and hepatic lipid profile of aging rats after treated with EcN-5	131
4.4	SCFAs concentration in colonic content of aging rats treated with EcN-5	132
4.5	PQQ concentration in feces and liver of aging rats treated with PQQ secreting EcN-5	133

Chapter 5

5.1	Plasmids and bacterial strains used in the present study	141
5.2	Diet composition used for the study	143
5.3	PQQ production in vitro by different EcN strains.	149